With two amyloid immunotherapies in the clinic, it has become urgent to understand the factors that lead to ARIA, and how to avoid this sometimes-serious side effect. At the Alzheimer’s Association ...

Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

White-matter hyperintensities, a sign of damage to the brain’s vasculature, are common on MRI scans of people with Alzheimer’s disease. Do they indicate an independent vascular co-pathology, or are ...

Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...

ABCA7 is a familiar blip on the Alzheimer’s GWAS radar. At this year’s AD/PD conference, held March 17–21 in Copenhagen, Denmark, five scientists presented findings that help explain how this gene can ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Exercise helps stave off Alzheimer’s disease, but exactly how it does so is murky. In the February 18 Cell, scientists led by Saul Villeda at the University of California, San Francisco, offered one ...

A community cohort boasting 16,000 participants? A memory clinic that sees more than 2,000 patients per month? A countrywide goal of screening 80 percent of its aged population for AD? These are a few ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Tau PET correlates closely with cognitive decline in Alzheimer’s disease, making it a potential surrogate outcome measure. Yet in amyloid immunotherapy trials to date, this signal has not always ...